Longeviti Neuro Solutions, a prominent neurotechnology company specializing in innovative platform solutions for complex brain disorders, has named Tim Scannell, the former President & COO of Stryker Corporation, as the Chair of its Board of Directors. Additionally, the company has disclosed a strategic capital partnership with Soleus Capital amounting to $10 million, aimed at expediting recruitment, product development, and medical education initiatives in the United States and internationally.
With an extensive background in the medical device sector spanning over three decades, Tim Scannell’s appointment brings a wealth of experience to Longeviti Neuro Solutions. Having held various leadership roles within Stryker Corporation, including Group President of MedSurg & Neurotechnology and President and COO, Scannell’s strategic insights and industry acumen are expected to play a pivotal role in advancing Longeviti’s mission.
Longeviti’s collaboration with Soleus Capital, a healthcare investment firm based in Greenwich, CT, signifies a significant milestone for the company. The $10 million investment from Soleus Capital is structured to support key strategic initiatives at Longeviti, including talent acquisition, further development of groundbreaking neurotechnology platforms, expansion of market presence, and the continuous delivery of innovative solutions to enhance patient care.
Jesse Christopher, Co-Founder and CEO of Longeviti Neuro Solutions, expressed enthusiasm about Tim Scannell’s appointment, emphasizing the invaluable leadership and expertise he brings to the organization. Together with the capital infusion from Soleus Capital, Longeviti is poised for accelerated growth, enabling the team to drive essential research, develop life-changing solutions for patients with complex brain disorders, and expand their impact within the neurotechnology landscape.
Tim Scannell shared his eagerness to contribute to Longeviti’s journey, praising the company’s visionary leadership and commitment to revolutionizing the neuro industry. His role as Chair of the Board will involve providing strategic guidance, leveraging his vast experience to shape Longeviti’s trajectory towards continued success and innovation in the field of neurotechnology.
Key Takeaways:
– Tim Scannell’s appointment as Chair brings extensive industry experience and strategic leadership to Longeviti Neuro Solutions.
– Longeviti’s partnership with Soleus Capital, backed by a $10 million investment, marks a significant milestone for the company’s growth and expansion.
– The collaboration aims to accelerate talent acquisition, drive further development of neurotechnology platforms, and enhance patient care for those with complex brain disorders.
– Longeviti’s mission to develop innovative solutions for brain surgery has already impacted over 4,000 patients globally, with products approved in 120 hospitals worldwide.
Read more on finance.yahoo.com